HRS 1893
Alternative Names: HRS-1893Latest Information Update: 29 Jul 2024
At a glance
- Originator Shandong Suncadia Medicine
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypertrophic cardiomyopathy
Most Recent Events
- 23 Jul 2024 Shandong Suncadia Medicine plans a phase I trial in Hypertrophic cardiomyopathy in China (PO) in July 2024 (NCT06516068)
- 20 May 2024 Shandong Suncadia Medicine completes the phase I pharmacokinetics trial in Hypertrophic cardiomyopathy (In volunteers) in China (PO) (NCT06354556)
- 26 Apr 2024 Shandong Suncadia Medicine initiates a phase I trial for Hypertrophic cardiomyopathy (In volunteers) in China (PO) (NCT06354556)